Watts D H, Koutsky L A, Holmes K K, Goldman D, Kuypers J, Kiviat N B, Galloway D A
Department of Obstetrics and Gynecology, University of Washington, Seattle 98195-6460, USA.
Am J Obstet Gynecol. 1998 Feb;178(2):365-73. doi: 10.1016/s0002-9378(98)80027-6.
Our purpose was to evaluate the risk of perinatal transmission of human papillomavirus.
Pregnant women were evaluated at <20 weeks' and between 34 and 36 weeks' gestation for genital human papillomavirus by clinical and colposcopic examination and by polymerase chain reaction. Their 151 infants were evaluated at birth, 6 weeks, and 6, 12, 18, 24, and 36 months of age for detection of human papillomavirus deoxyribonucleic acid by polymerase chain reaction on samples from the mouth, external genitalia, and anus. Polymerase chain reaction was performed with human papillomavirus L1 consensus primers and hybridization to human papillomavirus types 6, 11, 16, 18, 31, 33, 35, 39, and 45 and to a generic probe.
During pregnancy 112 (74%) of 151 women had historic, clinical, or deoxyribonucleic acid evidence of genital human papillomavirus infection. At 479 infant visits, human papillomavirus deoxyribonucleic acid was detected from only five (1.5%) of the 335 genital, four (1.2%) of the 324 anal, and none of the 372 oral or nasopharyngeal specimens. A positively reacting specimen was obtained from three (4%) of 80 infants born to women with human papillomavirus deoxyribonucleic acid detected at 34 weeks' gestation and from five (8%) of 63 born to women without human papillomavirus deoxyribonucleic acid (p = 0.47). All positive results in the infants were positive only with the generic probe and were preceded or followed by negatively reacting specimens. No clinical manifestations of human papillomavirus infection were detected in any infant.
The isolated detection of unclassified human papillomavirus types from infants at only single visits may represent low-level genital or nongenital human papillomavirus or may represent contamination. Although perinatal transmission of human papillomavirus is not ruled out by these data, the upper 95% confidence interval for detection of perinatal transmission from women with any evidence of genital human papillomavirus was only 2.8%.
我们的目的是评估人乳头瘤病毒围产期传播的风险。
通过临床和阴道镜检查以及聚合酶链反应,在妊娠小于20周以及34至36周时对孕妇进行生殖道人乳头瘤病毒评估。对她们的151名婴儿在出生时、6周龄以及6、12、18、24和36月龄时进行评估,通过聚合酶链反应检测来自口腔、外生殖器和肛门样本中的人乳头瘤病毒脱氧核糖核酸。使用人乳头瘤病毒L1共有引物进行聚合酶链反应,并与人乳头瘤病毒6、11、16、18、31、33、35、39和45型以及通用探针进行杂交。
在孕期,151名女性中有112名(74%)有生殖道人乳头瘤病毒感染的病史、临床或脱氧核糖核酸证据。在479次婴儿访视中,仅在335份生殖器样本中的5份(1.5%)、324份肛门样本中的4份(1.2%)检测到人乳头瘤病毒脱氧核糖核酸,而在372份口腔或鼻咽样本中均未检测到。在妊娠34周时检测到人乳头瘤病毒脱氧核糖核酸的女性所生的80名婴儿中有3名(4%)获得阳性反应样本,在未检测到人乳头瘤病毒脱氧核糖核酸的女性所生的63名婴儿中有5名(8%)获得阳性反应样本(p = 0.47)。婴儿所有的阳性结果仅与通用探针呈阳性反应,且在之前或之后有阴性反应样本。在任何婴儿中均未检测到人乳头瘤病毒感染的临床表现。
仅在单次访视时从婴儿中分离检测到未分类的人乳头瘤病毒类型可能代表低水平的生殖道或非生殖道人乳头瘤病毒,也可能代表污染。尽管这些数据不能排除人乳头瘤病毒的围产期传播,但有任何生殖道人乳头瘤病毒证据的女性围产期传播检测的95%置信区间上限仅为2.8%。